Under the guidance of the innovative concept, the gene technology company successfully developed a series of products. One typical successful case is Herceptin, a drug specifically developed for breast cancer conditions that overproduce the HER2 gene. Patients with HER2 gene breast cancer account for only one quarter of the total number of breast cancer patients. The market prospect for Herceptin was not promising from the beginning. However, after it was launched on the market, its efficacy was quite significant. In 2003 alone, Herceptin's sales reached 425 million US dollars.